Some investors may be asking whether CVS Health offers good value at around its recent price, or whether much of the potential upside in the stock has already been realized. Over the past year, CVS ...

CVS Health (CVS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

CVS is a slow-growing business, and minimal growth in Medicare Advantage rates should exacerbate that trend. The company's margins are lean, which can make it difficult for CVS to absorb headwinds and ...

Pharmacy retailer CVS Health (NYSE: CVS) is coming off an impressive bounce-back year in 2025 when its share price soared by 77%. A year earlier, it looked as if it was in an endless tailspin, falling ...

CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

CVS Health Corporation is rated a Buy with an 18% upside to a $97 price target, citing robust business momentum and undervaluation. CVS posted a strong FQ2 2025 double-beat, with revenue up 8.4% and ...

CVS Health CVS is scheduled to report third-quarter 2025 results on Oct. 29, before the market opens. The Zacks Consensus Estimate for third-quarter earnings per share (EPS) suggests a 24.8% increase ...

Shares of CVS Health (NYSE: CVS) have been declining recently as a potentially lower-than-expected increase in Medicare Advantage rates has investors worried about companies with exposure to health ...